The P-III (HIMALAYA) clinical trial evaluates the safety & efficacy of Imjudo (300mg) + Imfinzi (1500, q4w) vs sorafenib in unresectable HCC patients (n=1324) with no prior systemic therapy
For patients being treated with Imjudo + Imfinzi (STRIDE regimen), results demonstrated a m-OS of 16.4mos. vs 13.8mos for sorafenib, OS rate at 36mos. of 30.7% vs 19.8% & OS rate at 48mos. of 25.2% vs 15.1%
The 4-year follow-up data depicted that a single priming dose of STRIDE regimen reduced the risk of death by 22% vs sorafenib as out of the patients treated with the STRIDE regimen, 25.2% were alive at 4yrs. vs 15.1% for sorafenib
Ref: Businesswire | Image: AstraZeneca
Related News:- AstraZeneca Reports P-III Trial (DUO-E) Results of Imfinzi (durvalumab) + Lynparza (olaparib) for Advanced Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
